COVAXIN: Bharat Biotech has published the results of a candidate vaccine administered to animals in trials
New Delhi:
Bharat Biotech, which is developing the COVAXIN coronavirus vaccine in its latest report, has said that an animal study has shown that a candidate vaccine has helped develop a strong immune response to the highly infectious coronavirus.
“To summarize, the candidate vaccine was found to elicit strong immune responses. Therefore, it prevents infection and disease in primates after large amounts of exposure to the live SARS-CoV-2 virus,” Bharat Biotech posted on his website. Web.
“These results demonstrate protective efficacy in a live viral challenge model,” the company tweeted.
He said that 20 rhesus macaques divided into four groups received the candidate vaccine.
“One group was given a placebo, while three groups were immunized with three different candidate vaccines at zero and 14 days. All macaques were exposed to the viral challenge 14 days after the second dose,” said Bharat Biotech.
“The results showed a protective efficacy, increasing the specific IgG of SARS-CoV-2 and neutralizing antibodies, reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkeys. No evidence of pneumonia was observed in histopathological examination of the vaccinated groups, unlike the placebo group. No adverse events were observed in animals immunized with a two-dose vaccination regimen, “said Bharat Biotech.
Bharat Biotech proudly announces the results of the COVAXIN ™ animal study: these results demonstrate the protective efficacy in a live viral challenge model.
Read more about the results here: https://t.co/f81JUSfWpD@icmr_niv#BharatBiotech#COVAXIN#Safety#Vaccine# SARS-CoV-2pic.twitter.com/fva1SOcLOr
– BharatBiotech (@BharatBiotech) September 11, 2020
Bharat Biotech began human trials in July after gaining approval from the country’s drug regulatory body.
Although COVAXIN was initially planned to be launched on August 15, government officials later told a permanent parliamentary committee that such a drug would not be possible until at least next year.
Globally, more than 100 vaccines are being developed and tested to try to stop the COVID-19 pandemic, which has killed hundreds of thousands and devastated the global economy.
The possible COVID-19 vaccine from the University of Oxford that has been licensed to AstraZeneca is probably the world’s leading candidate and the most advanced in terms of development. But it has stopped after one of the subjects in the trials showed an adverse reaction.
.
